A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia

Beta Thalassemia Major Anemia Clinical Trial

Official title:
An Open-label, Dose-escalation, Dose-finding, and Proof-of-concept Trial of SP-420 in Subjects With Transfusion-dependent β-thalassemia

Status Recruiting

Clinical Trial Summary

The goal of this clinical trial is to learn about SP-420 ability to remove iron from organs in subjects with transfusion-dependent β-thalassemia. The main questions it aims to answer are: - How efficient is SP-420 in cleaning iron from the liver? - How is the safety and tolerability of ascending doses of SP-420? Participants will: - Take medication three time weekly - Attend up to 20 site visits - Undergo MRI scans

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05693909
Study type	Interventional
Source	Pharmacosmos A/S
Contact	Pharmacosmos Clinical and non-clinical Department
Phone	+45 5948 5959
Email	info@pharmacosmos.com
Status	Recruiting
Phase	Phase 2
Start date	September 4, 2023
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04962984` - Thrombin Generation in Beta-thalassemia Major	N/A
Completed	`NCT03591575` - Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children	Phase 4
Completed	`NCT03948737` - The Effect of Alpha-tocopherol in Hemolysis and Oxidative Stress Marker on the Red Cell Membrane Beta-thalassemia Major	N/A
Recruiting	`NCT02984475` - The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major	Phase 4